PVLA · Palvella Therapeutics, Inc.

Track PVLA — free

$122.96 +2.66 (+2.21%) At close · Oct 19

Russell 2000 member Rebalance outlook locked

Market Cap

$1.73B

14.41M

Volume · Oct 19 271.69K Avg daily vol (3M) 212.9K

Up next

Next earnings call

Nov 1, 2026 Est · unconfirmed · in 2 wks

Latest filing: 10-Q

filed Aug 4, 2026

Q2 2026 earnings call transcript

call held Aug 4, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$1.35M

Trailing 12 months

Net income (TTM)

−$61.70M

Trailing 12 months

Revenue growth YoY

-100.0%

Year over year

Operating margin

-27.7%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$250.58M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+29.9%

Year over year · more shares

Price change (1Y)

+64.5%

Trailing year

Short interest

17.5%

Latest settlement · 10.7 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 4, 2026

Q2 FY26

TL;DR. Palvella initiated the rolling NDA for QTORIN rapamycin in microcystic lymphatic malformations (first module submitted) and remains on track to complete the submission in 2H 2026 and target potential FDA approval in 1H 2027, while also planning a Phase 3 start in cutaneous venous malformations in Q4 2026, expanding its launch sales force to ~40 reps and guiding to $85–$95M of 2026 cash spend off a $251M cash balance.

Bullish

+ Rolling NDA initiated with first module submitted and completion on track for 2H 2026, targeting potential FDA approval in 1H 2027
+ Strong balance sheet of $250.6M provides runway through potential launch
+ Planned launch sales force expanded to ~40 reps at upper end of prior range
+ Phase 2 LOTU in angiokeratomas dosing initiated with topline data expected 2H 2027; Phase 2 DSAP study also planned for 2H 2026

Bearish

− 2026 cash burn guidance raised to $85–$95M following launch-readiness and pipeline expansion
− Q2 net loss widened to $21.9M versus $9.5M prior year, driven by higher R&D and G&A
− FDA did not initially grant Breakthrough Therapy designation for cutaneous venous malformations
− R&D expenses more than doubled to $12.5M and G&A more than doubled to $8.9M year over year

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Sell Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 20 · elevated Equity put/call 0.65

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −2%

below

Price vs 50-day avg −15%

below

RSI (14) 37

neutral

MACD trend Negative

52-week position 60%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return −20%

trailing

6-month return −2%

trailing

YTD return +17%

this year

Relative strength −10%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $145 › 200d $125 — 50d above 200d

Institutional flow Accumulating

11 of 198 funds reported for Sep 30 · net +1.3K sh shares · +2 new

Insider flow Distributing

Net -$49.1K over 90 days · 100% sells

Short interest Rising

17.52% of float · ▲ +8.5% MoM · 10.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

198 holders — near 2-yr high, broad support

Squeeze score 72

high risk · 0–100

Fundamentals

Strong

Revenue growth +65%

Y/Y

EPS growth +53%

Y/Y

Free cash flow $-25.2M

Quant / Vol

risk profile

Very High

Volatility 83%

annualized · 1-yr

Max drawdown −31%

past year

ATR 5.8%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the Earnings Call filed Aug 4, 2026

Cash expenses · this year $85M – $95M

Prior guidance period ended · from the 8-K filed Nov 10, 2025

Projected cash at year end · 2025 $55M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell

2 · 5 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−2% Neutral

Price vs 50-day avg

−15% Bearish

RSI (14)

37 Neutral

MACD trend

Negative Bearish

52-week position

60% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $145 › 200d $125 — 50d above 200d

Institutional flow Accumulating

11 of 198 funds reported for Sep 30 · net +1.3K sh shares · +2 new

Insider flow Distributing

Net -$49.1K over 90 days · 100% sells

Short interest Rising

17.52% of float · ▲ +8.5% MoM · 10.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

198 holders — near 2-yr high, broad support

Price context

position in its 52-week range

Range low $70 Now $123 · 60% Range high $158

vs 200-day avg -2% vs 50-day avg -15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Inbound patient inquiries	70	current	—
Shares outstanding	15,802,768	as of July 31, 2026	—
Target clinics engaged	200	current	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
PVLA Palvella Therapeutics, Inc. this stock	$1.73B	+17.5%	+65.3%	—	17.5%
VRTX Vertex Pharmaceuticals Inc / Ma	$127.73B	+10.7%	+46.2%	29.4	1.8%
MRNA Moderna, Inc.	$87.04B	+669.4%	+4.3%	—	7.7%
REGN Regeneron Pharmaceuticals, Inc.	$81.41B	+1.3%	+20.8%	19.6	2.1%
CSLLY Csl Ltd	$64.50B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

200

% held: 101.1%
Reported: 11 of 198
Top holder: SUVRETTA CAPITAL MANAGEME…

Held Float

View

Held by Funds

Fund positions

190

View

Short & Settlement

Short Interest Rising

Shares short

2.5M

Days to cover: 10.7d
Change: +198.4K sh

View

Short Volume

Short vol %

39%

As of: Oct 19, 2026

Short Total

View

Fails to Deliver

FTD shares

862

Value: $136.3K
As of: Sep 23, 2026

View

Off-Exchange

Off-exchange %

45.1%

Week of: Sep 14, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$49.1K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Financials

Revenue (FY)

$42.8M

Net income (FY): $-41.7M
EPS diluted: $-3.71

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 15, 2026
This year: 26

View

Proposed Sales

Value

$3.7M

Shares: 27.5K
Filed: Oct 13, 2026

View

Earnings & Events

Webcasts

Last webcast

Sep 15, 2026

View

Investor Relations

Upcoming events

View

Performance

	5D	20D	120D	MTD	YTD
PVLA	-8.5%	-19.9%	-2.4%	-10.9%	+17.5%
SPY	-1.5%	-0.9%	+7.7%	+0.5%	+12.4%
vs SPY	-7.0%	-18.9%	-10.1%	-11.4%	+5.1%

Key facts CIK 1583648 CUSIP 697947109 13F (30d) 13 filings 13 filers Visit website Investor relations

PVLA · Palvella Therapeutics, Inc.

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance